SF4521

Purpose

This bill changes how hospitals are paid for certain advanced biological products used in cell or gene therapy to treat rare diseases. It aims to create a separate inpatient reimbursement track, but only if the drug manufacturer agrees to participate in a value-based arrangement with the state and after federal approval of required documentation.

Main Provisions

• Effective date: July 1, 2025.
• Conditioned on federal approval: The separate reimbursement is contingent on the necessary federal approval of documentation required to enter into a value-based arrangement under section 256B.0625 subdivision 13k.
• New inpatient reimbursement for specific products: The commissioner may provide separate reimbursement to hospitals for biological products provided in the inpatient hospital setting as part of cell or gene therapy to treat rare diseases as defined in United States Code title 21 section 360bb, but only if the drug manufacturer enters into a value-based arrangement with the commissioner.
• Calculation of the reimbursement rate: The separate reimbursement rate for these biological products will be established based on the same methodology used for drugs administered in an outpatient setting under section 256B.0625 subdivision 13e paragraph e.
• Payment method: Hospitals must be paid the actual acquisition cost for biological products provided under the above provision.

Significant Changes to Law

• Introduces a dedicated, separate inpatient reimbursement pathway for biological products used in cell or gene therapy for rare diseases.
• Links reimbursement to manufacturers entering a value-based arrangement with the state, introducing a performance- or outcome-based payment component.
• Requires federal approval of specific documentation before the new reimbursement can apply.
• Aligns inpatient reimbursement methodology with the outpatient drug reimbursement framework already used in Minnesota statutes.

Definitions and Key Terms Used in Provisions

• Biological products
• Cell therapy
• Gene therapy
• Inpatient hospital setting
• Rare diseases (as defined in United States Code title 21 section 360bb)
• Value-based arrangement
• Commissioner
• Documentation required to enter into a value-based arrangement
• Outpatient setting
• Reimbursement methodology (as used in section 256B.0625 subdivision 13e paragraph e)
• Actual acquisition cost

Practical Effect and Implications

• Hospitals could receive separate reimbursement for certain high-cost biologic therapies delivered in the hospital setting, potentially improving financial coverage for these treatments.
• The requirement for a value-based arrangement means manufacturers may need to agree to performance- or outcome-based terms with the state to access this reimbursement pathway.
• Because federal approval of documentation is needed, the new system depends on federal action, which could affect timing and implementation.

Relevant Terms - biological products - cell therapy - gene therapy - inpatient hospital setting - rare diseases - 21 U.S.C. 360bb - value-based arrangement - commissioner - documentation - federal approval - 256B.0625 - subdivision 13k - outpatient setting - 256B.0625 subdivision 13e paragraph e - actual acquisition cost